NCT05901935View on ClinicalTrials.gov

DP303c in Patients With HER2-positive Advanced Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2028

Conditions
HER2-positive Advanced Breast Cancer
Interventions
DRUG

DP303c

DP303c injection, 3.0 mg/kg, Q3W.

DRUG

Trastuzumab

IV, 6 mg/kg, D1, Q3W

DRUG

Vinorelbine Tartrate

IV, 25 mg/m\^2，D1、D8，Q3W

DRUG

Capecitabine tablets

PO 1000 mg/m\^2, bid, D1-D14, Q3W

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY